ArticleAmerican journal of translational research2025
Circ_0007429 promotes hepatocellular carcinoma resistance to sorafenib through the miR-377-3p/THBS1 axis.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo elucidate the function of circ_0007429 in hepatocellular carcinoma (HCC) chemoresistance, with a focus on its regulatory mechanisms via the miR-377-3p/THBS1 (Thrombospondin 1) axis.
methodsThe expression levels of circ_0007429, miR-377-3p, and THBS1 mRNA were quantified using quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR). Cell viability was assessed with the CCK-8 assay, and THBS1 protein expression was evaluated by western blotting. The interactions between miR-377-3p and circ_0007429 or THBS1 were confirmed using luciferase reporter assays.
resultsCirc_0007429 expression was substantially upregulated in sorafenib-resistant (SR) HCC cells. Knockdown of circ_0007429 accelerated sorafenib sensitivity by suppressing cell survival. Mechanistically, circ_0007429 acted as a molecular sponge for miR-377-3p, whose activity was increased upon circ_0007429 silencing. THBS1 was recognized as a downstream target of miR-377-3p, and its expression was suppressed by miR-377-3p. Circ_0007429 is a ceRNA for miR-377-3p, thus controlling THBS1 translation and contributing to sorafenib resistance.
conclusionCirc_0007429 silencing enhances sorafenib sensitivity in HCC through the miR-377-3p/THBS1 axis. circ_0007429 may be a biomarker and therapeutic target for overcoming chemoresistance in HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.